<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="159714">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01846494</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00042419</org_study_id>
    <secondary_id>Pro00044788</secondary_id>
    <nct_id>NCT01846494</nct_id>
  </id_info>
  <brief_title>Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)</brief_title>
  <acronym>CARE-Hep C</acronym>
  <official_title>Longitudinal Assessment of Cardiovascular and Renal Health in Patients With Hepatitis-C (CARE-Hep C)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <authority>United States: Federal Government</authority>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to monitor the cardiovascular and renal health of patients who
      previously took BMS-986094 (an investigational medication for hepatitis C) in comparison to
      hepatitis C infected patients who have never taken BMS-986094.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2018</completion_date>
  <primary_completion_date type="Anticipated">April 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational [Patient Registry]</study_type>
  <study_design>Observational Model: Case Control, Time Perspective: Prospective</study_design>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Cardiovascular dysfunction</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess incidence of cardiovascular dysfunction among subjects exposed to BMS-986094  and compare with a similar population of HCV subjects who were not exposed to BMS-986094.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Renal dysfunction</measure>
    <time_frame>5 years</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assess incidence of renal dysfunction among subjects exposed to BMS-986094 and compare with a similar population of HCV subjects who were not exposed to BMS-986094.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">160</enrollment>
  <condition>Hepatitis C</condition>
  <arm_group>
    <arm_group_label>Hepatitis C Virus (HCV) patients exposed to BMS-986094</arm_group_label>
    <description>Hepatitis C infected patients with previous exposure to BMS-986094</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HCV patients not exposed to BMS-986094</arm_group_label>
    <description>Hepatitis C patients without exposure to BMS-986094</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Plasma, serum, and urine
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Hepatitis C positive subjects previously exposed to BMS 986094 and Hepatitis C positive
        subjects not previously exposed to BMS 986094.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Subjects will be enrolled based on prior enrollment in the BMS 986094 studies or
        treatment-naïve HCV subjects with no known cardiovascular abnormalities.

          1. All Subjects must give informed consent prior to participation in the study.

          2. Subject participated in the Phase 1 or Phase 2 trials with BMS 986094 (including
             placebo arm) OR

          3. Subject with known hepatitis C (Control)

               1. No previous exposure to BMS 986094

               2. Treatment naive at study entry (No prior hepatitis C treatment experience at the
                  time of enrollment, including but not limited to: standard interferon, pegylated
                  interferon, ribavirin, boceprevir, telaprevir, or other experimental drugs for
                  hepatitis C).

        Exclusion Criteria

          1. For subjects who participated in the Phase 1 or Phase 2 trials with BMS 986094, there
             are no exclusion criteria

          2. For the control group of subjects without exposure to BMS 986094, the following
             exclusion criteria, based on clinically available data, apply:

               1. Signs or symptoms of decompensated liver disease such as variceal bleeding,
                  ascites, hepatic encephalopathy, active jaundice defined by an indirect
                  bilirubin &gt;2, ALT or AST laboratory values ≥ 10 times the upper limit of normal,
                  or other evidence of decompensated liver disease or hepatocellular carcinoma

               2. Chronic liver disease other than HCV not limited to Hepatitis B virus (positive
                  test for HBsAg), hemochromatosis, auto-immune hepatitis, alcoholic liver disease
                  or non-alcoholic fatty liver disease

               3. History of liver transplantation

               4. Co-infection with HIV (positive test for anti-HIV Ab)

               5. Prior history of cardiomyopathy (ejection fraction ≤ 50%) or history of heart
                  failure

               6. Signs or symptoms of decompensated heart failure or

               7. Prior history of coronary artery disease, acute myocardial infarction or
                  coronary artery revascularization (percutaneous or coronary artery bypass
                  grafting)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Adrian F. Hernandez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Clinical Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jennifer Murphy</last_name>
    <phone>919-668-8795</phone>
    <email>jennifer.murphy@duke.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Anaheim Clinical Trials</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tuan Nguyen, MD</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Quest Clinical Research</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Jacob Lalezari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kansas City Gastroenterology and Hepatology</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Bradley Freilich, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asheville Gastroenterology Associates, PA</name>
      <address>
        <city>Asheville</city>
        <state>North Carolina</state>
        <zip>28801</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>William Harlan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Options Health Research</name>
      <address>
        <city>Tulsa</city>
        <state>Oklahoma</state>
        <zip>74104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Harvey Tatum, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Central Texas Clinical Research</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>David Wright, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Alamo Medical Research</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78215</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Eric Lawitz, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fundacion de Investigation de Diego</name>
      <address>
        <city>San Juan</city>
        <zip>00927</zip>
        <country>Puerto Rico</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 9, 2014</lastchanged_date>
  <firstreceived_date>May 1, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Hepatitis</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
